Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2-PREDICT
2023-508830-33-00Phase 2Authorised
- Sponsor
- SOLTI
- Start
- Dec 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in cancer, sponsored by SOLTI. Primary endpoints: Identification of optimal ERBB2 mRNA cut-point predictive of DS-8201a response and Correlation of ERBB2 mRNA levels with overall response. Planned start Dec 2023; status: authorised.
02
Drugs
trastuzumab deruxtecan
03
Conditions
cancer
Beyond the preview
Go deeper on 2023-508830-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508830-33-00.